Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
NCT07242534 on ClinicalTrials.gov · last registry update 2026-01-21
Recruiting now, toward 62 participants. Due to report February 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Number of good quality blastocysts (GQB). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Fundacion Dexeus
- Sponsor type
- Other
- Enrollment
- 62
- Started
- 2026-01-19
- Primary completion
- 2027-02 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of good quality blastocysts (GQB)
Conditions studied
Infertility · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.